A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in BRAF V600E colorectal cancer (CRC) models. Patients with refractory BRAF V600–mutant metastatic CRC (mCRC) were treated with a selective RAF kinase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: van Geel, Robin M.J.M., Tabernero, Josep, Elez, Elena, Bendell, Johanna C., Spreafico, Anna, Schuler, Martin, Yoshino, Takayuki, Delord, Jean-Pierre, Yamada, Yasuhide, Lolkema, Martijn P., Faris, Jason E., Eskens, Ferry A.L.M., Sharma, Sunil, Yaeger, Rona, Lenz, Heinz-Josef, Wainberg, Zev A., Avsar, Emin, Chatterjee, Arkendu, Jaeger, Savina, Tan, Eugene, Maharry, Kati, Demuth, Tim, Schellens, Jan H.M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546207/
https://ncbi.nlm.nih.gov/pubmed/28363909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados